



TUESDAY, SEPTEMBER 20TH



9:00-09:20 : WELCOME AND INTRODUCTION (KURSAAL CONF ROOM)

Introductory words, **Sylvain Perruche**, RIGHT Institute, Besançon, FR
Welcome words from the urban community's President and the Region's President
Introduction by **Marco Ruella**, UPENN, Philadelphia, USA

9:20-12:30 : CAR-T CELLS (KURSAAL CONF ROOM)

Chairmen : **Dr Christophe Ferrand** and **Dr Marina Deschamps**, RIGHT institute, Besançon, FR

09:20 : DECODING THE MODES OF ACTION OF CAR T CELLS USING INTRAVITAL IMAGING

Dr Philippe Bousso, Institut Pasteur and Inserm, Paris, FR

09:50 : ENDOWING UNIVERSAL CAR T-CELL WITH IMMUNE-EVASIVE PROPERTIES USING TALEN-GENE EDITING

Dr Julien Valton, Celsectis, Paris, FR

10:20 : GOLD SPONSOR PITCH (X2)

10:30 : BREAK

11:00 : CHINESE EXPERIENCE AND LANDSCAPE OF CART-CELLS IN CHINA

Pr Huang He, Bone Marrow Transplantation Center and Institute of Hematology, Zhejiang University, Hangzhou, PRC

11:30 : IS HOSPITAL EXEMPTION AN ALTERNATIVE OR A BRIDGE TO EUROPEAN MEDICINES AGENCY FOR DEVELOPING
ACADEMIC CHIMERIC ANTIGEN RECEPTOR T-CELL IN EUROPE?

SPANISH PUBLIC/ACADEMIC EXPERIENCE IN CART IN ACUTE LYMPHOID LEUKEMIA AND MULTIPLE MYELOMA

Dr Álvaro Urbano Ispizua, Clínic de Barcelona, SP

12:00 : DESCAR-T REGISTRY: LESSONS LEARNED FROM THE FRENCH REAL-LIFE DATABASE FOR CAR T CELLS IN
HEMATOLOGIC MALIGNANCIES

Pr Roch Houot, UMR INSERM U1236, Rennes, FR

12:30 : GOLD SPONSOR PITCH

12:35-14:00 : LUNCH (KURSAAL BALLROOM)

13:00-16:30 : B2B MEETINGS

14:00-16:15 : VISIT OF BIOINNOVATION

16:00-16H30 : BREAK

16:30-19:30 : UPCOMING INNOVATIVE THERAPIES (KURSAAL CONF ROOM)

Chairmen : **Dr Suman Mitra**, INSERM, Lille, FR and **Dr Sylvain Perruche**, RIGHT Institute, Besançon, FR

16:30 : CELL THERAPY IN STROKE

Pr Olivier Detante, Grenoble Institute of Neurosciences, Grenoble, FR

17:00 : TRANSLATION IN CELL AND GENE THERAPY : STATUS, CHALLENGES AND OPPORTUNITIES

Dr Miguel Forte, International Society for Cell & Gene Therapy, Charleroi, BE

17:30 : OPTIMIZING FUNCTIONS OF ADOPTIVELY TRANSFERRED TUMOR-SPECIFIC T CELLS

Dr Nathalie Labarriere, INCIT, UMR1302, Nantes, FR

18:00 : GOLD SPONSOR PITCH

18:05 : BREAK

18:30 : NEW CLASS OF CANCER VACCINE BASED ON AN OFF-THE-SHELF ANTIGEN PRESENTING CELL LINE

Eric Halioua, PDC*line Pharma, Liege, BE

19:00 : CLINICALLY TRANSLATABLE CYTOKINE FACTORIES FOR CANCER IMMUNOTHERAPY

Dr. Omid Veisheh, Rice University, Houston, USA

20:00-23:30 : EVENING RECEPTION (KURSAAL BALLROOM)

WEDNESDAY SEPTEMBER 21ST

**9:00-12:00 : REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES
(KURSAAL CONF ROOM)**

Chairmen: **Dr Mathilde Girard**, ADHARA, subsidiary of the URGO group, Chenôve and **Dr Mathieu Guerriaud**, CREDIMI, Dijon, FR

09:00 : INNOVATION SANTE 2030 PLAN, HOW FRANCE CAN FACILITATE THE DEVELOPMENT OF INNOVATIVE THERAPIES ?
FOCUS ON THE BIOTHERAPY - BIOPRODUCTION INTEGRATORS NETWORK

Dr Emmanuel Dequier, 'Grand défi Biomédicaments', Secrétariat Général pour l'Investissement, Paris, FR

09:30 : ACCELERATING MEDICAL INNOVATION FROM RESEARCH TO PATIENTS

Dr Andreas Wallnöfer, Jeito Capital, Paris, FR

10:00 : Upcoming intervention

xx

10:30 : BREAK

11:00 : NEW CLINICAL TRIALS REGULATION: EUROPEAN COOPERATION FOR INNOVATION

Dr Claire Gérard, Agence nationale de sécurité du médicament et des produits de santé (ANSM), Lyon, FR

11:30 : RNA-BASED DRUGS AND REGULATION: TOWARDS A NECESSARY EVOLUTION OF THE DEFINITIONS ISSUED FROM THE
EUROPEAN UNION LEGISLATION

Dr Mathieu Guerriaud, CREDIMI, in collaboration with **Pr Evelyne Kohli**, INSERM LNC-UMR1231, Dijon, FR

12:00-14:00 : LUNCH (KURSAAL BALLROOM)

12:30-14:00 : B2B MEETINGS

14:00-17:00 RNA AS RAW MATERIALS & THERAPEUTICS (KURSAAL CONF ROOM)

Chairmen : **Dr Philippe DULIEU**, RD Biotech and **Pr Olivier ADOTEVI**, RIGHT Institute, Besançon, FR

14:00 : MESSENGER RNA-BASED THERAPEUTICS: CURRENT STATUS, OPPORTUNITIES AND CHALLENGES

Pr Chantal Pichon, Center for Molecular Biophysics - UPR4301 CNRS, Orleans, FR

14:30 : MicroRNA AS A TOOL FOR ENGINEERING NEXT GENERATION CAR T-CELLS

Dr Marco Alessandrini, Antion Biosciences, Geneva, CH

15:00 : INSIGHTS INTO THE PROCESS DEVELOPMENT AND MANUFACTURE OF mRNA VACCINES

Phill Challis, eTheRNA, Niel, BE

15:30 : BREAK

16:00 : A LENTIVIRAL PLATFORM FOR EFFICIENT AND SAFE RNA DELIVERY

Dr Pascale Bouillé, Flash Therapeutics, Toulouse, FR

16:30 : MODERNA'S mRNA PLATFORM AND APPLICATIONS TO VACCINES AGAINST INFECTIOUS DISEASES

Dr Carole Henry, Moderna, Cambridge, Massachusetts, USA

17:00-CONCLUSION END OF CONGRESS

17:15 - BEER PARTY